PubMed Health⌕ Search

Biomedical subjects

L Israel

Publications and source records attributed to L Israel.

At least 73 records · Page 4Linked to original sources
PubMed1984

High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer.

Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy. Cyclophosphamide, 1200 mg/m2 was administered intravenously (IV) on day 1 and 5-FU, 600 mg/m2 IV on days 1 through 5. Cycles were repeated every 21 days or on hematologic recovery. Twenty-eight of the 30 patients achieved a remission (16 partial, and 12 complete), i.e., a response rate of 93%, and a complete response rate of 40%. The actuarial survival rate at 43 months was 52% for the population as a whole, and 68% for patients who achieved a complete response. Hematologic toxicity was relatively severe and the initial doses had to be reduced by 20% in all patients between the second and fifth courses. No deaths due to either infection or bleeding were seen due largely to intensive supportive care. It is concluded that increasing the doses of a small number of drugs of proven efficacy may be more useful than increasing the number of drugs given in lower doses. Furthermore, this approach spares other effective drugs for second-line therapy.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1984

[Localized hyperthermia in the treatment of human deep tumors. 4 years' experience].

Localized hyperthermia was used on 86 adult patients with deep-seated tumours beyond therapeutic resources. The possibility of regression could be assessed in 71. Following treatment with an instrument producing 13.6 MHz radiofrequency waves, demonstrable regression was obtained in 28% of all cases and in 50% of the last 22 cases treated for a total of 20 hours divided into one-field sessions of at least 2 hours. Even in the absence of regression, the pain-killing effect was most conspicuous. Some physical and technological problems inherent in the method have yet to be solved, but undoubtedly localized radiofrequency hyperthermia has real possibilities in the treatment of deep-seated human tumours, and this without toxic hazards, which is quite unusual in cancerology.

Burns↗
PubMed1983

Bleomycin and cis-platinum with or without mitomycin C in 110 previously untreated patients with head and neck cancer.

Between November 1979 and October 1981, 110 consecutive patients with previously untreated, biopsy-proven squamous cell carcinoma of the head and neck, were treated by chemotherapy prior to scheduled surgery and/or radiotherapy. Two regimens of chemotherapy were used. The first 57 patients received cis-platinum, 20 mg/m2/day for 5 consecutive days and bleomycin 5 mg/m2/day as a continuous infusion over the same 5 days every 3 weeks (Regimen A). The next 53 patients received the same schedule and dose of cis-platinum, bleomycin 2.5 mg/m2 every 12 hours for the same 5 consecutive days and mitomycin C6 mg/m2 on day 1 of each cycle every 3 weeks (Regimen B). The number of courses administered prior to surgery and/or radiotherapy ranged from 1-4 depending on the otorhinolaryngologist's assessment of the optimal time for locoregional treatment. The overall response rate in regimen A was 78% (45/57) compared to 90% for regimen B (48/53). Complete responses were seen in 10/57 (18%) and 13/53 (25%) patients in regimens A and B, respectively. Eight of 57 patients in regimen A and 6/53 in regimen B refused further treatment and follow-up, and 7/53 patients in regimen B chose to pursue chemotherapy (in which methotrexate replaced bleomycin) rather than undergo surgery and/or radiotherapy. Five of these seven patients are surviving disease-free from 7-12 months. In regimen A, 31/57 patients are surviving with a median survival exceeding 15 months. In regimen B, 46/53 patients are surviving up to 14 months. Nausea and vomiting induced by cis-platinum were the major side effects, seen to a variable degree in all patients. No cis-platinum-induced renal toxicity was observed with the 5-day regimen and none of the patients had symptomatic bleomycin-induced pneumonitis. One patient had a bleomycin-induced skin rash which did not require discontinuation of therapy.

Adult↗
PubMed1983

Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum in combination with cyclophosphamide. An E.C.O.G. pilot study.

Twenty patients with Stage III and IV carcinoma of the ovary have been treated with a combination of cyclophosphamide and cis-platinum given every 3 weeks. Regarding toxicity, this combination probably included a too-high dose of CTX (1.1 g/m2 every 3 weeks). The response rate was 75% (15/20) but with a significant duration only for those patients who achieved a complete response (7/20). It was seen that, as usual, patients who have undergone extensive reductive surgery are more likely to respond. The regimen described gives results comparable to those of more aggressive combinations but did not achieve significant control of the disease.

Aged↗
PubMed1982

Interim results of EORTC protocol 08742: comparison, after irradiation of locally advanced squamous cell bronchial carcinoma, of abstention, immunotherapy, combination chemotherapy, or chemoimmunotherapy.

After irradiation of locally unresectable epidermoid bronchial carcinoma, 1 year of chemotherapy is significantly superior in delaying both local recurrences and distant metastases and prolonging the disease-free interval. However, BCG immunotherapy alone seems to be superior in terms of survival to no therapy, chemotherapy, and immunochemotherapy. This could be due to a better tolerance to secondary treatments given at time of recurrence.

Carcinoma, Squamous Cell↗
PubMed1982

Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer.

Acute-phase reactant proteins reach abnormally high levels in patients with cancer, and correlate with the extent of disease. In this study, several acute-phase glycoproteins, and serum albumin as a control, were tested at different concentrations for their ability to modify the blastogenic response of lymphocytes from 30 normal donors to PHA and the chemotactic response of monocytes from 15 normal donors to casein. In high concentrations approximating those found in cancer patients, but not in normal concentrations, haptoglobin and fibrinogen inhibited both functions to different degrees. Orosomucoid inhibited only monocyte chemotaxis, while ceruloplasmin and alpha 1-antitrypsin affected neither function. Increasing concentrations of PHA did not overcome the blocking effect of haptoglobin and fibrinogen on blastogenesis, suggesting that PHA-protein interaction was not responsible for the effect observed. The three proteins that did not suppress blastogenesis individually did so strongly when combined. It is suggested that these glycoproteins, synthesized by the liver in response to an inflammatory stimulus, may act as 'non-specific blocking factors' protecting tumors against the host's immunological attack. This non-specific blocking activity of the acute-phase proteins may contribute to the 'immune escape' of the tumor.

Ceruloplasmin↗
PubMed1982

[Results of several times daily treatment by cisdiamine-platinum and bleomycin. Therapeutical considerations (author's transl)].

Seventy two head and neck cancers have been treated with a combination of Cis-DDP (20 mg/m2/day) and bleomycin (6 mg/m2/day, 24 hours infusion) given for 5 days 3 courses every 3 weeks in preoperative cases and for 6 days (4 courses every 3 weeks) in non preoperative cases. Fifteen patients treated for local recurrence after irradiation experienced no significant response and their actual survival at 12 months is 22%. For the other patients the objective response rate was 78% with 10 complete responses and the projected survival at 12 months varies from 62% to 92% according to the subsequent treatment (irradiation or surgery followed by irradiation). These results are in agreement with a few reports using similar combinations; but it needs to answer new questions about possibility of surgical strategy variations in the cases of good or complete responses with such a chemotherapy.

Bleomycin↗
PubMed1981

Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer.

A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases. Patients in Study 1 received bleomycin, CCNU, or streptozotocin and those in Study 2 received tilorone, Baker's antifol, or a combination of 5-fluorodeoxyuridine plus arabinosyl cytosine. Partial responses were seen only with bleomycin, Baker's antifol, and 5-fluorodeoxyuridine plus arabinosyl cytosine. The median times to treatment failure ranged from 3.6 weeks to 5.7 weeks, and the median survival times, from 8 weeks to 25 weeks for tilorone and bleomycin, respectively. Toxic reactions was primarily hematologic and gastrointestinal, but skin, neurologic, respiratory, and renal abnormalities were noted in some treatment arms. The treatment schedules outlined and the toxic effects noted provide background information that might prove useful in designing complex new chemotherapeutic programs, since there is pharmacological rationale for incorporating some of the agents tested into present standard combination chemotherapy regimens.

Antineoplastic Agents↗
PubMed1980

[Stewart-Treves syndrome (author's transl)].

Thirteen years after a right mastectomy with axillary node dissection completed by radiotherapy, a 78-year-old woman still had lymphoedema of the homolateral upper limb. The development of an angiosarcomatous tumour on the medial surface of the right arm led to a diagnosis of Stewart-Treves syndrome, this lesion considered by some to be metastasis of carcinoma of the breast and by others as a separate clinicopathological entity close to primary cutaneous angiosarcomas.

Aged↗